Cover Image

Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis

Yinxue Zhou,1,&ast; Tingyu Wu,2,&ast; Jiaxing Sun,1 Huanhuan Bi,1 Yuting Xiao,1 Yanmei Shao,1 Weizhong Han,1 Hongmei Wang1 1Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China; 2Department of Joint Surg...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhou Y (Author), Wu T (Author), Sun J (Author), Bi H (Author), Xiao Y (Author), Shao Y (Author), Han W (Author), Wang H (Author)
Format:	Book
Published:	Dove Medical Press, 2024-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
by: Hyein Ahn, et al.
Published: (2018)

Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer
by: He H, et al.
Published: (2023)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Luwei Han, et al.
Published: (2021)

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC
by: Shao J, et al.
Published: (2024)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)

Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells
by: Duc-Hiep Bach, et al.
Published: (2018)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021)

Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia
by: Widiasari Ni Putu Ayu, et al.
Published: (2023)

Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review
by: Xiaofei Gu, et al.
Published: (2024)

Deciphering breast cancer dynamics: insights from single-cell and spatial profiling in the multi-omics era
by: Xin Xiong, et al.
Published: (2024)

A case of Ph+ acute lymphoblastic leukemia and EGFR mutant lung adenocarcinoma synchronous overlap: may one TKI drug solve two diseases?
by: Qi Zhang, et al.
Published: (2024)

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Lijing Jiao, et al.
Published: (2019)

Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca2+ overload-induced ferroptosis
by: Yinyun Ni, et al.
Published: (2023)

Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells
by: Pedro Barrios-Bernal, et al.
Published: (2022)

Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
by: Najah Albadari, et al.
Published: (2024)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients
by: I. H. Bartelink, et al.
Published: (2022)

Stevens-Johnson syndrome induced by toripalimab in a previously EGFR-TKI-treated advanced lung adenocarcinoma patient harboring EGFR mutations 19 del/T790M/C797S in trans and cis: a case report
by: Yang Chen, et al.
Published: (2023)

Decipher the mechanisms of polymyxin resistance in Acinetobacter baumannii by genome-scale metabolic modelling
by: J Zhao, et al.
Published: (2020)

EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits
by: Eszter Bencze, et al.
Published: (2022)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients
by: Liantao Guo, et al.
Published: (2024)

Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
by: Xuanhong Jin, et al.
Published: (2024)

A Bibliometric Analysis of Mesenchymal Stem Cell-Derived Exosomes in Acute Lung Injury/Acute Respiratory Distress Syndrome from 2013 to 2022
by: Zhou W, et al.
Published: (2023)

Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
by: Yue Zeng, et al.
Published: (2022)

Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients
by: Liu J, et al.
Published: (2019)

Deciphering the Role of LncRNAs in Osteoarthritis: Inflammatory Pathways Unveiled
by: Hu K, et al.
Published: (2024)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
by: Pacini L, et al.
Published: (2021)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
by: Brian J. Thomas, et al.
Published: (2023)

Integrating Network Pharmacology and Experimental Validation to Decipher the Mechanism of Action of Huanglian Jiedu Decoction in Treating Atherosclerosis
by: Liang J, et al.
Published: (2021)

The TKI Era in Chronic Leukemias
by: Danilo De Novellis, et al.
Published: (2021)

Insight into the characteristics of research published in traditional, complementary, alternative, and integrative medicine journals: a bibliometric analysis
by: Jeremy Y. Ng
Published: (2021)

Deciphering the Mechanism of Xijiao Dihuang Decoction in Treating Psoriasis by Network Pharmacology and Experimental Validation
by: Guo Y, et al.
Published: (2023)

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
by: Dantong Sun, et al.
Published: (2021)

Bibliometric Analysis of Anesthetic Drugs’ Effects on Immune Function- Current Knowledge, Hotspots and Future Perspectives
by: Wang Y, et al.
Published: (2023)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
by: Jin Lei, et al.
Published: (2022)

Integrating Network Pharmacology and Experimental Validation to Decipher the Mechanism of Action of Astragalus–Atractylodes Herb Pair in Treating Hepatocellular Carcinoma
by: Liang Y, et al.
Published: (2024)

Deciphering EIF3D’s Role in Immune Regulation and Malignant Progression: A Pan-Cancer Analysis with a Focus on Colon Adenocarcinoma
by: Zhou Y, et al.
Published: (2024)